Aura Biosciences, Inc.
AURA$428M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaBOSTON106 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
3
Next Catalyst
Mar 31, 2026
3dMarket Overview
Stock performance and key metrics
AURA News
Catalyst Timeline
3 upcoming, 0 past
Phase 2Next
AU-011 Phase 2 Results Expected
Mar 31, 2026EstimatedAU-01124
Primary completion for AU-011 trial (NCT06643884) in Eye Cancer
Source2 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bel-sar | Phase 3 | Choroidal Melanoma | - | - |
Light-activated AU-011 | Phase 2 | Uveal Melanoma | - | - |
AU-011 | Phase 2 | Eye Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply